Neurocrine shares sink on news of indiplon delay

Shares of Neurocrine Biosciences took a nasty hit after the company announced that it would delay a resubmission of its FDA application for the sleep drug indiplon while reporting third quarter losses. Neurocrine now plans to focus on a resubmission of its low-dose version of indiplon after a new three month safety and efficacy study and will delay a resubmission of its high-dose version until the summer of 2008. Neurocrine had said it would resubmit the drug by the end of the first half of next year. Neurocrine reported a third-quarter loss of $39 million which was triggered after Pfizer pulled out of its collaboration on indiplon following the FDA's rejection of the high-dose version of the sleep drug.

- see the release on Neurocrine's move

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.